Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05106400 · ClinicalTrials.gov registry record · Phase 1

Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

A Phase 1 study of Healthy, sponsored by Scilex Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT05106400: Completed Phase 1 study of Healthy, sponsored by Scilex Pharmaceuticals.

NCT05106400 is a Phase 1 study of Healthy that has completed, run by Scilex Pharmaceuticals. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05106400, a Phase 1 study of Healthy, has completed, sponsored by Scilex Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The study is designed to evaluate and compare the clinical adhesion performance of the ZTlido (Lidocaine Topical System) 1.8% of Scilex Pharmaceuticals Inc. (Reference) versus Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) and IcyHot (Lidocaine 4% + Menthol 1% Patch), on the Mid to upper back while being worn for 12 hours in healthy adult human subjects.

Primary Outcome

The adhesion performance (i.e., degree of lifting or detachment) is assessed by clinicians at each time point. The adhesion of Test Products 1, 2, and 3 (each over-the-counter external analgesic lidocaine-containing patch) are compared to the adhesion performance observed for the Reference Product.

Conditions Studied

Interventions

  • DRUG ZTlido (Lidocaine Topical System) 1.8%
  • DRUG Salonpas (Lidocaine Patch 4%)
  • DRUG Aspercreme (Lidocaine Patch 4%)
  • DRUG IcyHot (Lidocaine 4% + Menthol 1% Patch)

Study Locations (1)

Minnesota

  • AXIS Clinicals - Dilworth

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2021-07-01
Est. Completion 2021-07-21
Phase Phase 1
Scilex Pharmaceuticals

7 total trials

What the finished NCT05106400 record still lists

NCT05106400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which ZTlido (Lidocaine Topical System) 1.8% is the first listed.

NCT05106400 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05106400 about?

NCT05106400 is a clinical study titled "Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches". The study is designed to evaluate and compare the clinical adhesion performance of the ZTlido (Lidocaine Topical System) 1.8% of Scilex Pharmaceuticals Inc. (Reference) versus Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) and IcyHot (Lidocaine 4% + Menthol 1% Patch), on the Mid to u...

What is the current status of trial NCT05106400?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-07-01. Estimated completion is 2021-07-21.

What conditions does trial NCT05106400 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05106400?

The interventions under investigation include: ZTlido (Lidocaine Topical System) 1.8% (DRUG), Salonpas (Lidocaine Patch 4%) (DRUG), Aspercreme (Lidocaine Patch 4%) (DRUG), IcyHot (Lidocaine 4% + Menthol 1% Patch) (DRUG).

Who is sponsoring clinical trial NCT05106400?

This trial is sponsored by Scilex Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05106400 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05106400's enrollment target sits among peer trials

24 791st of 1090 higher than 254 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05106400, the US trial registry maintained by the National Library of Medicine. NCT05106400 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.